Takatoshi Fujishita

Minami, 8111347, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma.

Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma.

Journal: Japanese journal of clinical oncology
Published: May 03, 2026

Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression.

Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression.

Journal: Immuno-oncology technology
Published: November 24, 2025

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

Journal: Annals of surgical oncology
Published: June 20, 2025

Combination of radiofrequency ablation and intramedullary nailing for the treatment of femoral metastases: single-center, retrospective observational study.

Combination of radiofrequency ablation and intramedullary nailing for the treatment of femoral metastases: single-center, retrospective observational study.

Journal: World journal of surgical oncology
Published: June 05, 2025

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Journal: Therapeutic advances in medical oncology
Published: October 16, 2024

Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.

Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.

Journal: Investigational new drugs
Published: September 23, 2022

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.

Journal: Frontiers in oncology
Published: June 10, 2022

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.

Journal: BMJ open
Published: June 08, 2022

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.

Journal: Thoracic cancer
Published: August 07, 2021

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.

Journal: Frontiers in oncology
Published: May 01, 2021

Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.

Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.

Journal: Thoracic cancer
Published: March 28, 2021

Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.

Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.

Journal: OncoTargets and therapy
Published: January 11, 2021
Showing 1-12 of 38

Last Updated: 09/26/2026